Matthew Rabinowitz

When I started Natera, the idea that you could screen a fetus for chromosomal abnormalities from a blood draw in the mother's arm sounded far-fetched. The standard was amniocentesis — needle into the womb, real risk, and so invasive that many parents simply chose not to do it. We believed fetal DNA in the mother's blood could be read accurately enough to change that. It took years of signal processing, modeling, and a lot of convincing. But it worked. Panorama has now supported millions of pregnancies worldwide. That wasn't the finish line. It was proof that biology, when viewed through the right computational lens, is still largely untapped. I spoke with Maria Bartiromo on Fox Business about where this goes next.

We are incredibly proud to share that the FDA has approved Signatera™ CDx as a companion diagnostic for use with adjuvant atezolizumab (Tecentriq®) in muscle-invasive bladder cancer. This is the first FDA-approved molecular residual disease (MRD) companion diagnostic in history – a milestone to celebrate on many levels! Today’s news speaks volumes to the transformation well underway in MRD-guided cancer care. Signatera has become a cornerstone of precision oncology, with extensive support from more than 185 peer-reviewed publications. By detecting microscopic amounts of tumor DNA in the blood, Signatera can identify MRD earlier than standard tools, allowing physicians to intervene sooner and improve outcomes for patients. Just as importantly, Signatera can help identify patients who are MRD-negative and may be able to avoid unnecessary therapy and its associated toxicity. Altogether, this has a tremendous impact on the lives of patients and their loved ones. This approval was supported by the landmark Phase III IMvigor011 study, published in The New England Journal of Medicine, which demonstrated the power of MRD-guided treatment decisions in bladder cancer. We’d like to thank our esteemed collaborators at @Genentech and @Roche, the principal investigators of IMvigor011, and our clinical trial participants for their contributions to this major milestone in cancer care. Read the full press release here: ow.ly/M0GZ50Z0isa #PrecisionMedicine #Oncology #Natera

Enjoyed my conversation with @MariaBartiromo on @FoxBusiness, where we discussed the future of early cancer detection, cancer vaccines, and where AI is already beginning to change outcomes in healthcare. foxbusiness.com/video/63957430…

📺 Tune in TOMORROW at 7pm ET on @FoxBusiness! This week, @MariaBartiromo speaks with: 💼 House China Select Committee Member @RepZachNunn (R-IA) 📊 Heritage Foundation Chief Economist @RealEJAntoni 💉 Natera Co-Founder and Executive Chairman @MattRVerse

After all of that, this felt more like something I owed rather than a career choice. The engineer in me doesn’t dwell; he builds, so that’s what I did.

About 15 years ago, I lost a child to a genetic condition. I've kept that private for a long time. I'm starting to talk about it now. It was medically horrific. And it made everything that came after feel not optional, necessary.

Sat down with @GrinsteinJ on the Behind the Breakthroughs podcast to talk genomic diagnostics — where it's been, where it's going, and why most people are still sleeping on how big this is. insideprecisionmedicine.com/topics/molecul…

AI on imaging is already powerful, but combine it with polygenic risk scores and new-onset diabetes biomarkers, and you start to flip the model entirely. Instead of reacting after something shows up on a scan, we can begin to identify who should be scanned in the first place.

We talk a lot about trillion-dollar problems. Rare disease is one of the most under-recognized ones. A big part of that cost comes down to something we can actually fix: patients waiting years for answers.

Just joined @GrinsteinJ on @Inside_PM's Behind the Breakthroughs podcast. We covered a lot of ground – noninvasive prenatal testing, AI-driven disease prediction, and why the convergence of genomics and computation is the most consequential shift happening in medicine right now. Worth a listen: insideprecisionmedicine.com/topics/molecul…

Join our Data and AI experts for our upcoming webinar, Driving clinical trial strategy with MRD-powered RWD and AI. Register here: ow.ly/qHyu50YVLoI We'll discuss how to: • Use MRD-driven insights to assess treatment response earlier in development • Interrogate molecular RWD to refine trial design, feasibility, and cohort selection • Apply AI-driven approaches to characterize patients and disease risk more efficiently • Translate RWD and AI insights into actionable development strategies, with recent case examples. Thank you to our speakers: Matt Love, VP Business Development RWD and AI, Natera Jenny Park, Sr. Director Product Development RWD and AI, Natera Erik Bergstrom, PhD Machine Learning Scientist, Natera #Natera #ctDNA #MRD

We're at the 33rd Annual TRI-CON in San Francisco! Connect with us to learn more on:  • Comprehensive, whole-genome screening identifies high-risk patients missed by traditional tools  • We are advancing EHR integration to deliver dynamic risk insights that evolve with the patient's clinical journey  • We are training AI models to detect diseases earlier and enable more timely, precision-driven care Learn more about how our approach is helping clinicians move from reactive care to proactive, personalized medicine: myome.com

Hello 👋 from booth #541 at #ACOG2026! Our team is here to share how Natera continues to advance prenatal genetic care. #Natera #ACOG @ACOG

See you at #ACOG2026! Stop by booth #541 to speak with our experts and explore how Natera continues to advance prenatal genetic care. There's still time to register for our dinner presentation, An Inside Look: Landmark EXPAND data supporting Fetal Focus™ and Natera’s future product roadmap, here: ow.ly/CQQc50YTcvk #Natera #ACOG @ACOG